Clinical effect of flunarizine combined with betastatin in the treatment of cervical vertigo

Objective To investigate the clinical effect of flunarizine combined with betastatin in the treatment of cervical vertigo and its effects on vascular endothelin-1(ET-1)and calcitonin gene related peptide(CGRP)levels in patients. Methods A total of 120 patients with cervical vertigo admitted to our hospital were selected, and were divided into two groups according to random throwing method. The patients in two groups were all given pushing moxibustion therapy of traditional Chinese medicine based on basic treatment. Control group orally administrated flunarizine, while the study group was additionally given oral administration of betastatin. Dizziness Handicap Inventory(DHI)score, clinical curative effect and drug-related adverse reactions of two groups before and after treatment were compared, and ET-1, CGRP levels in the two groups before and after treatment were compared. Results There was no significant difference in DHI score between the two groups before treatment(P>0.05). DHI scores at 2 and 4 weeks after treatment in the study group were lower than those in the control group(P<0.05). The effective rate of treatment in the study group was 95.00%, which was significantly higher than 81.67% in the control group(P<0.05). There were no significant differences in the levels of ET-1 and CGRP before treatment between the two groups(P>0.05). After treatment, the level of ET-1 in the study group was lower, and the level of CGRP was significantly higher than those in the control group(P<0.05). The incidence of adverse reactions in the study group was 16.67%, which was significantly higher than 11.67% in the control group, but no significant difference was found in two groups(P>0.05). Conclusion Flunarizine combined with betastatin in the treatment of cervical vertigo has a significant clinical effect for patients with cervical vertigo, and it can improve the serum ET-1 and CGRP levels.